2023/04/20
Lung Cancer Biomarkers | Delta-like Ligand 3 (DLL3)
As an important target for SCLC and other tumors, multiple therapies developed around DLL3 have developed rapidly in recent years. DLL3 drugs with bispecific antibodies, monoclonal antibodies, antibody-conjugated drugs (ADC), cell therapy, and bispecific T-cell bonding agents (BiTE) have made clinic
Learn more
2023/03/15
Inspiring Target: Integrin α4/β7 (LPAM-1)
To accelerate the research and development of integrin-targeting drugs, ACROBiosystems has a catalog of all 24 known integrin heterodimers, including integrin α4/β7, expressed through our HEK293 platform and verified by SEC-MALS.
Learn more
2023/05/06
Empowering Innovation to the Global Market with Acro Certify
Empowering Innovation to the Global Market with Acro Certify
Learn more
2023/06/06 - 2023/06/08
Antibody Engineering& Therapeutics Europe 2023
Speaker: ACROBiosystems and others
Time: June 6- June 8
Learn more